Anthony Petrone
Stock Analyst at Mizuho
(4.12)
# 480
Out of 5,147 analysts
218
Total ratings
55.62%
Success rate
11.23%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LNTH Lantheus Holdings | Maintains: Outperform | $72 → $85 | $74.91 | +13.47% | 8 | Feb 27, 2026 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $90 → $100 | $78.70 | +27.06% | 10 | Feb 25, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $21 → $22 | $25.30 | -13.04% | 3 | Feb 20, 2026 | |
| DXCM DexCom | Maintains: Outperform | $78 → $90 | $73.43 | +22.57% | 4 | Feb 13, 2026 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $130 → $85 | $64.51 | +31.76% | 8 | Feb 12, 2026 | |
| HAE Haemonetics | Maintains: Outperform | $90 → $80 | $63.32 | +26.34% | 17 | Feb 6, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $140 → $115 | $76.85 | +49.64% | 9 | Feb 5, 2026 | |
| EXAS Exact Sciences | Downgrades: Neutral | $85 → $105 | $103.38 | +1.57% | 2 | Jan 20, 2026 | |
| MDXG MiMedx Group | Maintains: Outperform | $12 → $10 | $4.89 | +104.50% | 5 | Dec 17, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $72 | $70.60 | +1.98% | 10 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $120 | $93.90 | +27.80% | 4 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $100 | $83.67 | +19.52% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $31.73 | +26.06% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $100 | $87.18 | +14.71% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $300 | $256.26 | +17.07% | 18 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $100 | $86.47 | +15.65% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $70 → $78 | $75.36 | +3.50% | 10 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $135 | $122.06 | +10.60% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $135 | $116.35 | +16.03% | 6 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $19.90 | -9.55% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $100 | $97.66 | +2.40% | 7 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $12 | $10.26 | +16.96% | 3 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $175 | $120.40 | +45.35% | 10 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $8.27 | +383.68% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $58 | $75.52 | -23.20% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $15.57 | -10.08% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $84.27 | +24.60% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $503.51 | -22.54% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $108.18 | -38.07% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $98.44 | +77.77% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $13.17 | +89.83% | 3 | May 13, 2020 |
Lantheus Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $72 → $85
Current: $74.91
Upside: +13.47%
Establishment Labs Holdings
Feb 25, 2026
Maintains: Outperform
Price Target: $90 → $100
Current: $78.70
Upside: +27.06%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $21 → $22
Current: $25.30
Upside: -13.04%
DexCom
Feb 13, 2026
Maintains: Outperform
Price Target: $78 → $90
Current: $73.43
Upside: +22.57%
Inspire Medical Systems
Feb 12, 2026
Maintains: Outperform
Price Target: $130 → $85
Current: $64.51
Upside: +31.76%
Haemonetics
Feb 6, 2026
Maintains: Outperform
Price Target: $90 → $80
Current: $63.32
Upside: +26.34%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $140 → $115
Current: $76.85
Upside: +49.64%
Exact Sciences
Jan 20, 2026
Downgrades: Neutral
Price Target: $85 → $105
Current: $103.38
Upside: +1.57%
MiMedx Group
Dec 17, 2025
Maintains: Outperform
Price Target: $12 → $10
Current: $4.89
Upside: +104.50%
LivaNova
Dec 17, 2025
Maintains: Outperform
Price Target: $70 → $72
Current: $70.60
Upside: +1.98%
Dec 17, 2025
Maintains: Outperform
Price Target: $100 → $120
Current: $93.90
Upside: +27.80%
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $83.67
Upside: +19.52%
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $31.73
Upside: +26.06%
Nov 11, 2025
Maintains: Outperform
Price Target: $110 → $100
Current: $87.18
Upside: +14.71%
Oct 31, 2025
Maintains: Outperform
Price Target: $310 → $300
Current: $256.26
Upside: +17.07%
Oct 31, 2025
Maintains: Outperform
Price Target: $90 → $100
Current: $86.47
Upside: +15.65%
Oct 23, 2025
Downgrades: Neutral
Price Target: $70 → $78
Current: $75.36
Upside: +3.50%
Aug 1, 2025
Maintains: Neutral
Price Target: $130 → $135
Current: $122.06
Upside: +10.60%
Jul 18, 2025
Maintains: Neutral
Price Target: $140 → $135
Current: $116.35
Upside: +16.03%
Jul 16, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $19.90
Upside: -9.55%
Jul 16, 2025
Maintains: Outperform
Price Target: $98 → $100
Current: $97.66
Upside: +2.40%
Jul 16, 2025
Maintains: Neutral
Price Target: $13 → $12
Current: $10.26
Upside: +16.96%
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $120.40
Upside: +45.35%
Apr 10, 2025
Initiates: Outperform
Price Target: $40
Current: $8.27
Upside: +383.68%
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $75.52
Upside: -23.20%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $15.57
Upside: -10.08%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $84.27
Upside: +24.60%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $503.51
Upside: -22.54%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $108.18
Upside: -38.07%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $98.44
Upside: +77.77%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $13.17
Upside: +89.83%